Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jakas

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|May 26, 2006
Tumor-cell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activityStefica Horvat, Kata Mlinarić-Majerski, Ljubica Glavas-Obrovac, et al.
Journal of Medicinal Chemistry|September 30, 1994
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonistsR A Daines, P A Chambers, D S Eggleston, et al.
Journal of Medicinal Chemistry|January 1, 1991
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activityW D Kingsbury, J C Boehm, D R Jakas, et al.
Journal of Medicinal Chemistry|March 1, 1989
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activityR P Hertzberg, M J Caranfa, K G Holden, et al.
The Journal of Antibiotics|January 1, 1976
Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK&F 60771)G L Dunn, J R Hoover, D A Berges, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2002
Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureusFrank Fan, Kang Yan, Nicola G Wallis, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis modelR M Keenan, M A Lago, W H Miller, et al.
Journal of Medicinal Chemistry|April 18, 2003
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabKMark A Seefeld, William H Miller, Kenneth A Newlander, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonistK W Ward, L M Azzarano, W E Bondinell, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|September 7, 1999
In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activityH M Sarau, J J Foley, D B Schmidt, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|May 26, 2006
Tumor-cell-targeted methionine-enkephalin analogues containing unnatural amino acids: design, synthesis, and in vitro antitumor activityStefica Horvat, Kata Mlinarić-Majerski, Ljubica Glavas-Obrovac, et al.
Journal of Medicinal Chemistry|September 30, 1994
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonistsR A Daines, P A Chambers, D S Eggleston, et al.
Journal of Medicinal Chemistry|January 1, 1991
Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activityW D Kingsbury, J C Boehm, D R Jakas, et al.
Journal of Medicinal Chemistry|March 1, 1989
Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activityR P Hertzberg, M J Caranfa, K G Holden, et al.
The Journal of Antibiotics|January 1, 1976
Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK&F 60771)G L Dunn, J R Hoover, D A Berges, et al.
Antimicrobial Agents and Chemotherapy|October 18, 2002
Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureusFrank Fan, Kang Yan, Nicola G Wallis, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a restenosis modelR M Keenan, M A Lago, W H Miller, et al.
Journal of Medicinal Chemistry|April 18, 2003
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabKMark A Seefeld, William H Miller, Kenneth A Newlander, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonistK W Ward, L M Azzarano, W E Bondinell, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|September 7, 1999
In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activityH M Sarau, J J Foley, D B Schmidt, et al.
Pageof 5